Journal of the American Heart Association · 12 Nov 2026
Safety and Efficacy of Apixaban Therapy for Coronary Artery Aneurysms After Kawasaki Disease
Annette L. Bakerh-index 1, Kimberlee Gauvreau, Francesca Sperotto, Amy Hellinger, Ryan J. Williams, Sarah D. de Ferranti, Audrey Dionne, Kevin G. Friedman, MaryBeth F. Son, Paul Esteso, Thomas J. Giorgio, Veronique C. Wright, Sunil J. Ghelani, Christina J. VanderPluym, Jane W. Newburgerh-index 21
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background Anticoagulation combined with aspirin lowers the risk of coronary thrombosis in patients with large/giant coronary artery aneurysms following Kawasaki disease. We aimed to evaluate the safety and efficacy of apixaban in this high‐risk pediatric population and compare it to conventional anticoagulant therapy. Methods In this retrospective study, we described our experience with the use of apixaban in patients with Kawasaki disease with large/giant coronary artery aneurysms. In patients who were previously exposed to conventional anticoagulation, we compared rates of new coronary thrombosis or myocardial infarction (effectiveness) and clinically relevant bleeding (safety) during apixaban versus antecedent conventional therapy. All patients received concomitant antiplatelet agents. Apixaban dosing was guided by weight and anti‐Xa chromogenic assays. Results Between 2018 and 2025, 28 patients with Kawasaki disease (median age 6.7 years; 75% male) with large/giant coronary artery aneurysms were prescribed apixaban. Of these, 27 (96%) had previously received vitamin K antagonists or low molecular weight heparin. The rates of new coronary thrombosis and new myocardial infarctions were not higher when patients received apixaban versus conventional anticoagulation (0.025 versus 0.041 events per person‐year; incidence rate ratio [IRR], 0.61 [95% CI, 0.06–3.3] and 0.013 versus 0.041 events per person‐year; IRR, 0.31 [95% CI, 0.01–2.5], respectively). Rates of clinically relevant bleeding were also not higher for apixaban versus conventional therapy (0.038 versus 0.058 events per person‐year, IRR, 0.66 [95% CI, 0.11–2.5]). Conclusions In this retrospective single‐center series of pediatric patients with Kawasaki disease with large/giant coronary artery aneurysms, apixaban combined with antiplatelet therapy was well tolerated and demonstrated no evidence of increased harm relative to conventional anticoagulants. Multicenter research is needed to confirm these findings and define the optimal therapeutic range for apixaban in this high‐risk population.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Jane W. Newburger has the highest h-index among the authors (21).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (27)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 7 more references
A free account opens the rest of the citing papers and references on every paper’s page.